Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy

BACKGROUND: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies. OBJECTIVE: To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing m...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohan, Stanley L, Edwards, Keith, Lucas, Lindsay, Gervasi-Follmar, Tiffany, O’Connor, Judy, Siuta, Jessica, Kamath, Vineetha, Garten, Lore, Chen, Chiayi, Thomas, James, Smoot, Kyle, Kresa-Reahl, Kiren, Spinelli, Kateri J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350141/
https://www.ncbi.nlm.nih.gov/pubmed/30729028
http://dx.doi.org/10.1177/2055217318824618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350141/
https://www.ncbi.nlm.nih.gov/pubmed/30729028
http://dx.doi.org/10.1177/2055217318824618

Ejemplares similares